Date: 2016-06-08
Type of information: Licensing agreement
Compound: paraxial mesoderm multipotent cells (P2MCs) technology
Company: Crispr Therapeutics (Switzerland - USA - MA) Anagenesis Biotechnologies (France)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: collaboration, licensing
Action mechanism: cell therapy. The P2MC technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into skeletal muscle stem cells, also known as satellite cells. The technology was developed with the support of AFM-telethon, INSERM-Transfert, CNRS and Université de Strasbourg.
Disease: all human muscle diseases including Duchenne muscular dystrophy (DMD)
Details:
- • On June 8, 2016, Crispr Therapeutics and Anagenesis Biotechnologies announced a strategic in-licensing and collaboration agreement, which grants Crispr Therapeutics exclusive worldwide license to Anagenesis' proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for cell therapy for all human muscle diseases. The agreement will support the advancement of CRISPR-based cellular therapies for the treatment of musculoskeletal diseases. Initial research will focus on Duchenne Muscular Dystrophy (DMD).
- Anagenesis is the third collaboration for CrisprTherapeutics in the past seven months, and follows agreements with Vertex Pharmaceuticals and Bayer. Each collaboration allows the company to access distinctive capabilities to bring new, potentially transformative gene-based medicines to patients with serious diseases. As part of this collaboration, Olivier Pourquié, PhD, scientific founder of Anagenesis and professor at Harvard Medical School and the Brigham and Women's Hospital, will serve as a consultant to CRISPR Therapeutics.
Financial terms:
Latest news:
Is general: Yes
